Document:

Exhibit
10.1

 

Convertible
Loan Extension Agreement

 

This
Convertible Loan Extension Agreement (“Extension”) is entered into as of October23, 2022 (the “Extension
Effective Date”), by and between Orgenesis Inc. (“Borrower”) and Yehuda Nir (“Lender”).
Borrower and Lender may each be referred to herein as a “Party,” and collectively as the “Parties”.
Any term not defined herein shall have the meaning ascribed to it in the CN (as defined below).

 

WHEREAS:
Lender and Borrower are parties to that certain Convertible Loan Agreement, dated April 21, 2022, ( “Original Effective
Date”), as amended on May 11, 2022 (“CN”), for the loan amount of US$ 5,000,000 attached hereto as Exhibit
A; and

 

WHEREAS:
Lender and Borrower wish to revise the terms of the CN in accordance with the terms herein;

 

NOW
THEREFORE, the Parties hereby agree as follows:

 

	1	Interest
                                            Rate

 

1.1 Commencing
as of the Original Effective Date, interest shall accrue on the unconverted and then outstanding Loan Amount at the rate of 10% per annum
(“Interest Rate”).

 

	2	Maturity
                                            Date Extension

 

2.1 The Maturity Date under the CN shall be extended from July 21, 2023 to January 20, 2024 (the “Maturity Date”).

 

	3	Warrants

 

3.1 The
Borrower shall issue the Lender a warrant registered in the name of such Lender, or in such nominee name(s) as designated by such Lender,
representing the right to purchase 1,111,111 shares of Common Stock, at an exercise price per share of $2.50 per share. Such warrant
will be exercisable at any time beginning six (6) months and one day after the Extension Effective Date and ending thirty-six (36) months
after the Extension Effective Date.

 

3.2 The
warrant in Section 3.1 above shall be in addition to Warrant dated April 21, 2022 and granted pursuant to Section 1(b) of the CN (the
“Original Warrant”).

 

	4	Conversion
                                            Price.

 

4.1 The
Conversion Price for conversion of the outstanding amount as defined in Section 2(a)a. of the CN shall be amended to “a price per
share of $2.50 per share” instead of $4.50 per share.

 

    	1

     

    

 

	5	Exhibit
                                            A. Exhibit A of the CN shall be amended as follows:

 

	Name of Lender	 	Loan Amount	 	Number of Warrants	 	Date
	Yehuda Nir	 	$	5,000,000	 	 	 	277,778	 	 	 	April 21st, 2022	 
	Yehuda Nir	 	 	 	 	 	 	1,111,111	 	 	 	October 23 , 2022	 
	Total	 	$	5,000,000	 	 	 	1,388,889	 	 	 		 

 

	6	General
                                            Provisions.

 

6.1 The
CN is hereby amended only to the extent necessary to give full effect to this Extension. Unless expressly specified herein, all other
terms and conditions specified in the CN shall apply and shall remain in full force and effect. Capitalized terms used not defined herein
shall have the meaning ascribed to them in the CN. In the event of any conflict between the terms of this Extension and the terms of
the CN, the terms of this Extension shall control. Without limiting the aforesaid, the Borrower hereby represents that all approvals
required with respect to this Extension have been obtained by the Borrower.

 

6.2 This
Extension may be executed in any number of counterparts, including in facsimile and scanned format, each of which shall be deemed an
original and enforceable against the Party actually executing such counterpart and all of which together shall constitute one and the
same instrument.

 

6.3 The
Borrower shall promptly make any and all reports required with respect to this Extension.

 

[Remainder
of Page Intentionally Left Blank]

 

    	2

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Extension to Convertible Loan Agreement as of the date first above written.

 

THE
LENDER:

 

	/s/ Yehuda Nir	 
	Yehuda Nir	 

  

	ORGENESIS
    INC.	 
	 	               	 
	By:
    	/s/
Vered Caplan	 

	Name:
    	Vered
    Caplan	 
	Title:
    	Chief
    Executive Officer	 

	Address:
    	20271
    Goldenrod Lane	 
	Germantown,
    Maryland, 20776 USA	 

 

[Signature
page to the Extension to Convertible Loan Agreement between Orgenesis Inc. and Yehuda Nir]

 

    	3

     

    

 

Exhibit
A - Convertible Loan Agreement

 

    	4Exhibit
10.2

 

Convertible
Loan Extension Agreement

 

This
Convertible Loan Extension Agreement (“Extension”) is entered into as of October 23, 2022 (the “Extension
Effective Date”), by and between Orgenesis Inc. (“Borrower”) and Ricky Neumann (“Lender”).
Borrower and Lender may each be referred to herein as a “Party,” and collectively as the “Parties”.
Any term not defined herein shall have the meaning ascribed to it in the CN (as defined below).

 

WHEREAS:
Lender and Borrower are parties to that certain Convertible Loan Agreement, dated May 19, 2022 (“CN” and “Original
Effective Date”) for the loan amount of US$ 3,000,000 attached hereto as Exhibit A; and

 

WHEREAS:
Lender and Borrower wish to revise the terms of the CN in accordance with the terms herein;

 

NOW
THEREFORE, the Parties hereby agree as follows:

 

	1	Interest
                                            Rate

 

1.1 Commencing
as of the Original Effective Date, interest shall accrue on the unconverted and then outstanding Loan Amount at the rate of 10% per annum
(“Interest Rate”).

 

	2	Maturity
                                            Date Extension

 

2.1 The Maturity Date under the CN shall be extended from August 19, 2023 to February 19, 2024 (the “Maturity Date”).

 

2.2 The
last paragraph of Section 1(a) of the CN shall be amended such that the Outstanding Amount may be prepaid by the Borrower, at its option,
in whole or in part at any time or (ii) at the Lender’s option, following any equity or debt financing or series of (related or
unrelated) financings by Borrower as of the Extension Effective Date. In the event that any subsidiary of Borrower raises financing (debt
or equity), Borrower will make reasonable commercial efforts (though not on account of such financing not occurring or requiring terms
substantially less beneficial to the subsidiary) to ensure that funds from such financing are received by Borrower so as to enable Borrower
to repay the Loan Amount.

 

	3	Warrants

 

3.1 The
Borrower shall issue the Lender a warrant registered in the name of such Lender, or in such nominee name(s) as designated by such Lender,
representing the right to purchase 666,666 shares of Common Stock, at an exercise price per share of $2.50 per share. Such warrant will
be exercisable at any time beginning six (6) months and one day after the Extension Effective Date and ending thirty-six (36) months
after the Extension Effective Date.

 

    	1

     

    

 

3.2 The
warrant in Section 3.1 above shall be in addition to Warrant Number W-302 dated May 19, 2022 and granted pursuant to Section 1(b) of
the CN (the “Original Warrant”).

 

	4	Conversion
                                            Price.

 

4.1 The
Conversion Price for conversion of the outstanding amount as defined in Section 2(a)a. of the CN shall be amended to “a price per
share of $2.50 per share” instead of $4.50 per share.

 

	5	Legal
                                            Fees. Upon execution hereof, the Borrower or one of its affiliates shall pay the legal
                                            fees of the Lender in an amount of US$7,500 plus VAT to Spero Levi & Co. upon receipt
                                            of an invoice for such amount.

 

	6	Exhibit
                                            A. Exhibit A of the CN shall be amended as follows:

 

	Name of Lender	 	Loan Amount	 	 	Number of Warrants	 	 	Date	 
	Ricky Neumann	 	$	3,000,000	 	 	 	166,667	 	 	 	May 19th, 2022	 
	Ricky Neumann	 	 	 	 	 	 	666,666	 	 	 	October 23, 2022	 
	Total	 	$	3,000,000	 	 	 	833,333	 	 	 		 

 

	7	General
                                            Provisions.

 

7.1 The
CN is hereby amended only to the extent necessary to give full effect to this Extension. Unless expressly specified herein, all other
terms and conditions specified in the CN shall apply and shall remain in full force and effect. Capitalized terms used not defined herein
shall have the meaning ascribed to them in the CN. In the event of any conflict between the terms of this Extension and the terms of
the CN, the terms of this Extension shall control. Without limiting the aforesaid, the Borrower hereby represents that all approvals
required with respect to this Extension have been obtained by the Borrower.

 

7.2 This
Extension may be executed in any number of counterparts, including in facsimile and scanned format, each of which shall be deemed an
original and enforceable against the Party actually executing such counterpart and all of which together shall constitute one and the
same instrument.

 

7.3 The
Borrower shall promptly make any and all reports required with respect to this Extension.

 

[Remainder
of Page Intentionally Left Blank]

 

    	2

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Extension to Convertible Loan Agreement as of the date first above written.

 

THE
LENDER:

 

	/s/ Ricky Neumann	 
	Ricky
Neumann	 

 

	ORGENESIS
    INC.	 
	 	               	 
	By:
    	/s/
    Vered Caplan	 

	Name:
    	Vered
    Caplan	 
	Title:
    	Chief
    Executive Officer	 

	Address:
    	20271
    Goldenrod Lane	 
	Germantown,
    Maryland, 20776 USA	 

 

[Signature
page to the Extension to Convertible Loan Agreement between Orgenesis Inc. and Ricky Neumann]

 

    	3

     

    

 

Exhibit
A - Convertible Loan Agreement

 

    	4Exhibit
10.3

 

AMENDMENT,
CONSENT AND

WAIVER AGREEMENT

 

This
Amendment, Consent and Waiver Agreement (the “Agreement”) is entered into as of October 23, 2022 (the “Effective
Date”), by and between Orgenesis Inc. (the “Corporation”) and the investors listed on the signature page
hereto (“PIPE Investors”) that acquired shares of common stock of the Corporation (the “Common Stock”)
pursuant to that certain Securities Purchase Agreement, dated as of March 30, 2022 (the “SPA”). The Corporation and PIPE
Investors may each be referred to herein as a “Party,” and collectively as the “Parties”.

 

WHEREAS,
the Corporation and the PIPE Investors are parties to a Registration Rights Agreement, dated as of March 30, 2022 (the “RRA”),
pursuant to which the Corporation agreed to register the resale of certain shares of Common Stock held by the PIPE Investors on a registration
statement on Form S-3 (the “Registration Statement”); and

 

WHEREAS,
the Corporation and the PIPE Investors wish to enter into an agreement pursuant to which the PIPE Investors shall (i) consent and agree
to an extension of the date for filing the Registration Statement to register the Registrable Securities (as defined in the RRA) to April
3, 2023 and the effective date of such Registration Statement as provided for in this Agreement; and (ii) waive any potential damages
or claims under the RRA with respect to the Corporation’s obligations under the RRA or SPA and release the Corporation therefrom;
and

 

WHEREAS,
in consideration for the consent, agreement, waiver and release described herein, the Corporation shall agree to issue additional warrants
to purchase shares of Common Stock to each PIPE Investor (the “Additional Warrants”) and such Additional Warrants shall have
an exercise price of $2.50 per share of Common Stock and be in the same form as the original Warrants issued pursuant to the SPA.

 

NOW
THEREFORE, the Parties hereby agree as follows:

 

	 	1.	Extension
    of Deadlines. Section 1 of the RRA shall be amended as follows:

 

a.
The definition of Effectiveness Deadline shall be deleted and replaced with the following:

 

“Effectiveness
Deadline” means, with respect to the Initial Registration Statement or the New Registration Statement, the 30th calendar day
following the Filing Deadline (or, in the event the Commission reviews and has written comments to the Initial Registration Statement
or the New Registration Statement, the 60th calendar day following the Filing Deadline); provided, however, if the
Effectiveness Deadline falls on a Saturday, Sunday or other day that the Commission is closed for business, the Effectiveness Deadline
shall be extended to the next day on which the Commission is open for business.

 

    	1

     

    

 

b.
The definition of Filing Deadline shall be deleted and replaced with the following:

 

“Filing
Deadline” means, with respect to the Initial Registration Statement, April 3, 2023.

 

	 	2.	Release;
    Waiver. Each PIPE Investor, on behalf of itself and each successor or assign of any of the foregoing (collectively, the “Releasing
    Parties”), hereby irrevocably and unconditionally releases and forever discharges the Corporation of and from any and all
    actions, causes of action, suits, proceedings, executions, judgments, duties, damages, interest, debts, dues, accounts, bonds and
    covenants (whether express or implied), and claims and demands whatsoever whether in law or in equity (whether based upon contract,
    tort, contribution or otherwise) which the Releasing Parties may have against the Corporation relating to not fulfilling its obligations
    under the RRA or the SPA that such Releasing Parties are parties to. The Releasing Parties consent and agree that the Releasing Parties
    shall not be entitled to any Liquidated Damages as provided in Section 2(c) of the RRA unless the Filing Deadline or the Effectiveness
    Deadline as amended herein are not met as amended herein.
	 	 	 
	 	3.	Warrant
    Issuance. In consideration for the agreement to extend the Filing Deadline and Effectiveness Deadline and the foregoing release
    and waiver as provided above, the Corporation shall issue to the PIPE Investors the number of Additional Warrants registered in the
    name of such PIPE Investor, or in such nominee name(s) as designated by such PIPE Investors as set forth in the table below. The
    Additional Warrants will represent the right to purchase that number shares of Common Stock as provided below, at an exercise price
    per share of $2.50 per share of Common Stock, in the same form of Warrant as set forth in the SPA. Such Additional Warrants shall
    be exercisable at any time beginning six (6) months and one day after the Effective Date and ending thirty-six (36) months after
    the Effective Date. 

 

	Name
    of PIPE Investor	 	Additional
    Warrants
	Ricky
    Steven Neumann	 	174,460

 

	 	4.	General
    provisions.

 

	 	a.	The
    RRA is amended only to the extent necessary to give full effect to this Agreement. Unless expressly specified herein, all other terms
    and conditions specified in the RRA shall apply and shall remain in full force and effect. Capitalized terms used not defined herein
    shall have the meaning ascribed to them in the RRA. In the event of any conflict between the terms of this Agreement and the terms
    of the RRA, the terms of this Agreement shall control.
	 	 	 
	 	b.	This
    Agreement may be executed in any number of counterparts, including in facsimile and scanned format, each of which shall be deemed
    an original and enforceable against the Party actually executing such counterpart and all of which together shall constitute one
    and the same instrument.
	 	 	 
	 	c.	This
    Agreement shall be effective upon execution of this Agreement by the Corporation and that number of PIPE Investors as required by
    the RRA.
	 	 	 
	 	d.	The
    receipt of this Agreement prior to execution hereof shall be deemed to be prior written notice to the Holders of any proposed waiver,
    amendment, modification or supplement.

 

[signature
page follows]

 

    	2

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement, as of the date first above written.

 

ORGENESIS
INC.

 

	/s/
    Vered Caplan	 
	Name:	Vered Caplan	 
	Title:	Chief Executive Officer	 
	 	 
	/s/ Ricky
    Steven Neumann	 
	Ricky Steven Neumann	 

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]